Zura Bio FY2025 EPS Forecast Boosted by Leerink Partnrs

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Zura Bio in a report released on Wednesday, December 11th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.64) for the year, up from their previous estimate of ($0.67). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio's FY2026 earnings at ($0.57) EPS.

Several other equities research analysts have also recently commented on ZURA. Chardan Capital lowered their price target on shares of Zura Bio from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, November 8th. Leerink Partners started coverage on shares of Zura Bio in a research report on Monday, November 4th. They set an "outperform" rating and a $15.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zura Bio in a research report on Wednesday. Piper Sandler reissued an "overweight" rating and set a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th. Finally, HC Wainwright reissued a "neutral" rating and set a $5.00 price objective on shares of Zura Bio in a research note on Monday, November 18th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $15.80.

Zura Bio Trading Up 0.9 %

ZURA traded up $0.02 during midday trading on Friday, hitting $2.22. The company had a trading volume of 310,138 shares, compared to its average volume of 337,086. Zura Bio has a twelve month low of $2.00 and a twelve month high of $6.35. The firm's 50-day simple moving average is $3.80 and its 200-day simple moving average is $3.82.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12).

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently modified their holdings of the business. Barclays PLC boosted its position in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company's stock valued at $260,000 after acquiring an additional 56,757 shares during the period. Geode Capital Management LLC lifted its position in Zura Bio by 70.6% during the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock worth $3,706,000 after purchasing an additional 377,545 shares during the period. Sphera Funds Management LTD. bought a new stake in Zura Bio during the third quarter worth about $2,999,000. State Street Corp lifted its position in Zura Bio by 47.5% during the third quarter. State Street Corp now owns 395,059 shares of the company's stock worth $1,604,000 after purchasing an additional 127,300 shares during the period. Finally, Braidwell LP bought a new stake in Zura Bio during the third quarter worth about $10,040,000. Institutional investors own 61.14% of the company's stock.

Insider Buying and Selling

In related news, Director Parvinder Thiara sold 1,001,633 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 22.10% of the stock is owned by corporate insiders.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.